REVISTA DE NEUMOLOGÍA

B I B L I O G R A F Í A
_______________________________

 

  1. Aboussouan LS. Acute exacerbations of chronic bronchitis. Postgraduate Med 1996;99:89-102.
  2. Allegra L, Cardaro Cl, Grassi A. Prevention of acute exacerbation s of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: A multicenter double-blind, placebo controlled trial. Respiration 1996; 63: 174-80.
  3. Ambrosino M, Nava S, Bertone fl Fracchia C, Rampulla C. Physiologic evaluation of pressure support ventilation by nasal mask in patients with stable COPD. Chest 1992; 101: 385-91.
  4. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies (statement). Am Rev Respir Dis 1991;144:1201-18.
  5. American Thoracic Society. American Thoracic Society statement: lung transplantation. Am Rev Respir Dis 1993; 147: 772-76.
  6. Angelillo VA, Bedi S, Durteee D. Eftects of low and high carbohydrate feedings in ambulatory patients with chronic obstructive pulmonary disease and chronic hypercapnia. Ann Intern Med 1985;103:883-85.
  7. Annonimous. Multicenter Study Group. Long-term oral acetylcysteine in chronic bronchitis, a double-blind controlled study. Eur J Respir Dis 1980;61:93-108.
  8. Anthonisen NR. Prognosis in chronic obstructive pulmonary disease: results from multicenter clinical trials. Am Rev Respir Dis 1989;133:595-99.
  9. Anthonisen NR, Connett JE, Kiley JP Eftects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rata of decline of FEV1. The lung Health Study. JAMA 1994;272:1497-505.
  10. Anthonisen NR, Manfreda J, Warren J. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
  11. Anthonisen NR, Manfreda J, Warrren CPW, et al. Antibiotic therapy in exacebartions of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
  12. Anthonisen NR, Wright EC, IPPB Trial Group. Bronchodilatar response in chronic obstructive pumonary disease. Am Rev Respir Dis 1986;133:814-19.
  13. ATS Statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 1995;152:577-S120.
  14. Badgett RG, Tanaka DJ, Hunt DK, et al. Can moderato chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone? Am J Med 1993; 94: 188-96.
  15. Bates DV In: Respiratory Function in Disease. New York: W-B- Saunders, 1989: 172-87.
  16. Bennett WD, Chapman WF, Mascarella JM. The acute eftect of ipratropium bromide bronchodilator therapy on cough clearance in COPD. Chest 1993;103:488-95.
  17. Bolan G, Broome CV Facklam RR. Pneumococcal vaccine efticacy in selected populations in the United States. Ann Intern Med 1986;104:1-6.
  18. Bone R. Combivent Inhalational Aerosol Study. Combination of ipratropium and albuterol is more eftective than either alone. Chest 1994;105:1411-19.
  19. Braun SR, Spratt G, Scott GC, Ellersieck M. Comparison of six oxygen delivery systems for COPD patients at rest and during exercise. Chest 1992;102:694-98.
  20. Bridgemann MM, Marsden M, Selby C, Morrison D, MacNee W. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 1994;49:670-75.
  21. Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic airway obstruction in a sample from the general population. N Engl J Med 1987;317:1309-14.
  22. Callahan C, Dittus RS, Katz BR Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1991; 114: 216-23.
  23. Celli BR. Pulmonary rehabilitation in patients with COPD. Am J Resp Crit Care Med 1995;152:861-64.
  24. Chapman KR. Therapeutic algorithm for chronic obstructive pulmonary disease. Am J Med 1991;91:17S23S.
  25. Chetty KG, Brown SE, Light RW. ldentification of pulmonary hypertension in chronic obstructive pulmonary disease from rutine chest radiographs. Am Rev Respir Dis 1982;126:338-41.
  26. Chodosh S. Treatment of acute exacerbations of chronic bronchitis: state of the art. Am J Med 1991;91:87S-92S.
  27. Cote TR, Stroup DF, Dwyer DM, Horan JM, Peterson DE. Chronic obstructive pulmonary disease mortality. A role for altitude. Chest 1993;103:1194-97.
  28. Couser JI jr, Guthmann R, Hanmadeh MA, Kane CS. Pulmonary rehabilitation improves exercise capacity in older patients with COPD. Chest 1995;107:730-34.
  29. Daniel TM, Chan BB, Bhaskar V et al. Lung Volume Reduction Surgery. Ann Surg 1996; 223: 526-33.
  30. Dompeling E, van Schayck PM, van Grunsven PM, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids: a 4-year prospective study. Ann Intern Med 1993;118:770-78.
  31. Donner CF, Howard P Pulmonary rehabilitation in chronic obstructive pulmonary disease (COPD) with recomendations. Eur Respir J 1992;5:226-75.
  32. Easton PA, Jadue C, Dhingra S, Anthonisen NR. A comparison of the bronchodilating effects of beta2-adrenergic agent (albuterol) and a anticholinergic agent (ipratropium broomide), given by aerosol alone or in sequence. N Engl J Med 1986;315:735-39.
  33. ERS Consensus Statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1398-420.
  34. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 1993; 328: lO17.22.
  35. Fisher EB, Haire-Joshu D, Morgan GD. Smoking and smoking cessation state of the art. Am Rev Respir Dis 1990.142:702-20.
  36. Fishman AP NIH Workshop Summary: Pulmonary Rehabilitation Research. Am J Resp Crit Cara Med 1994; 149: 825-33.
  37. Forrester HL, Jahnigen DW, Laforce FM. lnefficacy of pneumococcal vaccine in a high risk population. Am J Med 1987; 83: 425-30.
  38. Goldstein RS, Gort EH, Stubbing D, Avendano MA, Guyatt GH. Randomised controlled trial of respiratory rehabilitation. Lancet 1994; 344: 1394-97.
  39. Gong HJ. Air travel and oxygen therapy in cardiopulmonary patients. Chest 1992;101:1l04-13.
  40. Gould GA, Redpath AT, Ryan M. Parenchymal emphysema measured by CT lung density correlates with lung function in patients with bullous disease. Eur Respir J 1993.6:698-704.
  41. Guyatt GH, Townsend M, Barman LB, Pugsely SD. Quality of life in patients with chronic airflow limitation. Br J Dis Chest 1987; 81: 45-54.
  42. Hodgkin JE, Connors GL, Bell CW. Pulmonary rehabilitation: Guidelines to Success. Bd. Philadelphia: J. B. Lippincott, 1993.
  43. Howland J, Nelson EC, Barlow PB, et al. Chronic obstructive airway disease: impact of hea'th education. Chest 1986; 90: 233-38.
  44. Huchon G. Risk factors for chronic bronchitis and chronic obstructive lung disease. Respiration 1991; 58: 10-l2.
  45. Jenne JW. What role ofr theophylline therapy? Thorax 1994; 49: 97-1OO.
  46. Karpel JP Kotch A, Zinny M, Pesin J, Alleyne W. A comparison of inhaled ipratropium, oral theophylline plus inhaled $-agonist, and the combination of all three in patients with COPD. Chest 1994; l05:1089-94.
  47. Kesten S, Chapman KR. Physician perceptions and management of COPD. Chest 1993;104:254-58.
  48. Kesten s, Rebuck AS. ls the short-term response to inhaled beta-adrenergic agonist sensitive or specifioior distinguishing between asthma and COPD? Chest 1994; 105: 1042-45.
  49. Ketelaars CA, Schlosser MA, Mostert R, et al. Determinants of health-related quality of lite in patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 39-43.
  50. Kirsten DK, Wegner RE, Jorres RA, Magnussen H. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest 1993; 104:1101-07.